Loading…
← CockpitCompetitor Analysis › GHRS GH Research PlcOpen in the cockpit ↗

GH Research PlcGHRSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing fast-acting psychedelic-derived (5-MeO-DMT) treatments for treatment-resistant depression.

Momentum weak 22
Mkt cap
$1.25B
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$7.01M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 11.6%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$18.25
1D-0.1%
1W-5.2%
1M-4.8%
3M-36.4%
6M-19.0%
YTD+43.7%
1Y+29.4%
ATR %6.7%
Beta1.28
52w lowhigh42.0% off high

What GH Research does

Clinical-stage biotech developing fast-acting psychedelic-derived (5-MeO-DMT) treatments for treatment-resistant depression.

Has no medicine on sale, so it funds trials from money raised from investors, and revenue would arrive only after approval or a licensing deal. The business rests on one lead drug in one form of depression, so trial results move the whole company.

Products and services

  • GH001 (inhaled mebufotenin, TRD)
  • Other 5-MeO-DMT formulations

Where it sits in the supply chain

  • Biopharma R&D
  • Psychedelic-derived neuropsychiatric…
  • Clinical trials for depression

What could go right

  • Positive pivotal trial data
  • First-mover in fast-acting psychedelic therapy

What could go wrong

  • Regulatory novelty/scheduling risk
  • Binary clinical trial risk

Moat: none (IP / patents). Pre-commercial; must navigate a novel regulatory path for a psychedelic-derived psychiatric drug.

Headquarters: Dublin, Ireland · Founded: 2018 · Employees: 73

Named competitors

GH Research at a glance

Size GH Research (GHRS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.25B, the 2091st largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.25 on 18 Nov 2026.

Performance Over six months the shares fell 19.0%, against -15.6% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.

Short interest Short interest is 3.0% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 85GHRS 84
Six months, rebased to 100: GH Research against the median of its 20 peers (local-currency closes).

GH Research financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$359,000-$335,000-$315,000-$315,000-$47,000
EBITDA-$71.1M-$60.3M-$49.9M-$40.9M-$30.5M
Net income-$62.3M-$48.3M-$39.0M-$35.6M-$22.5M
Free cash flow-$52.5M-$43.7M-$42.3M-$33.4M-$26.3M
Capital expenditure$139,151$121,000$49,000$100,000$67,000
Total debt$360,000$512,000$624,000$974,000$0

Quarterly statements and history in the cockpit →

GH Research competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%688076300204000950GPCRAMPHAVLN002332300026IDIA347850LBRXHROW2616300006OCULINVAMNKD2493GHRS6-month return →1-month return →
Up and to the right = strong over both horizons. GH Research is the large dot.

GH Research competitors and peer comparison

Head to head with its named competitors (GHRS vs CMPS vs ATAI vs JNJ)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
GH Research GHRS$1.25B-19%n/an/an/an/a
COMPASS Pathways Plc Sponsored ADR CMPS$1.15B-25%n/an/an/an/a
AtaiBeckley ATAIn/a+81%n/an/an/an/a
Johnson & Johnson JNJ$656B+20%+8%26%6.9×3.7%

How GH Research compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

GH Research against its 20 peers (data as of 18 Nov 2026)
MeasureGHRSPeer medianRank in peer set
1-month return-4.8%-5.1%9th highest of 20
6-month return-19.0%-15.6%9th lowest of 20
Distance from 52-week high-42.0%-37.5%9th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%10.4×n/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%818.8×n/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%12.8×n/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Harrow HROWUnited States$1.21B+4%+21%1%4.7×n/an/a
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%17.0×n/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%10.4×44.1%-13.2%
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%17.0×n/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%2.2×-17.2%+3.9%
MannKind MNKDUnited States$1.31B+25%+32%-2%4.0×n/an/a
Mabwell (Shanghai) Bioscience 2493.HKHong Kong$1.20B-29%+21%-127%13.6×n/an/a
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a

Questions

Who are GH Research's main competitors?
Named competitors: Compass Pathways (CMPS), atai Life Sciences (ATAI), Johnson & Johnson (esketamine) (JNJ). The cockpit's measured peer set (industry) also includes Sinopep-Allsino Bio Pharmaceutical (688076.SS), Staidson (Beijing) Biopharmaceuticals (300204.SZ), C.Q. Pharmaceutical (000950.SZ), Structure Therapeutics, Inc. Sponsored ADR (GPCR), Amphastar Pharmaceuticals (AMPH), Avalyn Pharma (AVLN).
How has GH Research stock performed?
Over six months to 18 Nov 2026 the shares returned -19.0% against -15.6% for the median peer; over one year +29.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.